Empowered Patient Podcast

Dietrich Stephan PhD, CEO, NeuBase Therapeutics discusses the history of research into the genetic basis of all diseases, NeuBase's PATrOL™ platform allowing for intelligent design of drugs that engage with a malfunctioning gene, and the company's therapies in development for Huntington's disease and myotonic dystrophy, which Dr. Stephan describes as "heat seeking missiles" because they are so specific and targeted to the broken gene of interest.

@NeuBaseinc #RareDisease #GeneSilencing #HuntingtonsDisease #DM1 $NBSE

NeuBaseTherapeutics.com

Listen to the podcast here.

Dietrich Stephan PhD, CEO, NeuBase Therapeutics discusses the history of research into the genetic basis of all diseases, NeuBase's PATrOL™ platform allowing for intelligent design of drugs that engage with a malfunctioning gene, and the company's therapies in development for Huntington's disease and myotonic dystrophy, which Dr. Stephan describes as "heat seeking missiles" because they are so specific and targeted to the broken gene of interest.

@NeuBaseinc #RareDisease #GeneSilencing #HuntingtonsDisease #DM1 $NBSE

NeuBaseTherapeutics.com

Download the transcript here.

John Dimos, CEO, Fountain Therapeutics describes their approach to the treatment of age-associated diseases and points out that there is a big difference between chronological and biological age. In the search for finding a way to intervene in the aging process, Fountain is taking a hypothesis-free approach and with the aid of artificial intelligence, they are looking at cells holistically to find potential therapeutics that make old cells look and act more like young cells.

@FountainTX #aging #ArtificialIntelligence #AI #DrugDiscovery #AgingTherapeutics #DiseasesofAging

FountainTX.com

Listen to the podcast here

John Dimos, CEO, Fountain Therapeutics describes their approach to the treatment of age-associated diseases and points out that there is a big difference between chronological and biological age. In the search for finding a way to intervene in the aging process, Fountain is taking a hypothesis-free approach and with the aid of artificial intelligence, they are looking at cells holistically to find potential therapeutics that make old cells look and act more like young cells.

@FountainTX #aging #ArtificialIntelligence #AI #DrugDiscovery #AgingTherapeutics #DiseasesofAging

FountainTX.com

Download the transcript here

Anne Whitaker, CEO, Aerami Therapeutics talks about imatinib their inhaled treatment for the rare disease pulmonary arterial hypertension which could potentially be the first therapy on the market to actually reverse the disease. First approved as a cancer therapy, imatinib stops the progression of the stiffening and thickening of the blood vessels in the lungs and is delivered using a breath-activated, Bluetooth enabled, hand-held nebulizer device delivering the drug centrally in the lung and in the peripheral area.

@aeramiTx #inhaledtherapies #RespiratoryDiseases #PulmonaryArterialHypertension #PAH #imatinib

Aerami.com

Listen to the podcast here

Anne Whitaker, CEO, Aerami Therapeutics talks about imatinib their inhaled treatment for the rare disease pulmonary arterial hypertension which could potentially be the first therapy on the market to actually reverse the disease. First approved as a cancer therapy, imatinib stops the progression of the stiffening and thickening of the blood vessels in the lungs and is delivered using a breath-activated, Bluetooth enabled, hand-held nebulizer device delivering the drug centrally in the lung and in the peripheral area.

@aeramiTx #inhaledtherapies #RespiratoryDiseases #PulmonaryArterialHypertension #PAH #imatinib

Aerami.com

Download the transcript here

Apostolos Stathopoulos, CEO, ERC-Belgium talks about using immunotherapy to treat glioblastoma, the most malignant of all gliomas or brain cancers. ERC's therapy, which stimulates the patient's immune system to mount an immune response against the tumor cells, has demonstrated a clinically meaningful survival benefit with minimal toxicity and unprecedented regressions of this deadly disease.

#ERC #immunotherapy #glioblastoma #cancer

ERC-Immunotherapy.com

Listen to the podcast here

Apostolos Stathopoulos, CEO, ERC-Belgium talks about using immunotherapy to treat glioblastoma, the most malignant of all gliomas or brain cancers. ERC's therapy, which stimulates the patient's immune system to mount an immune response against the tumor cells, has demonstrated a clinically meaningful survival benefit with minimal toxicity and unprecedented regressions of this deadly disease.

#ERC #immunotherapy #glioblastoma #cancer

ERC-Immunotherapy.com

Download the transcript here

Ayla Annac, CEO and Co-Founder, InvivoSciences shines light on the next generation of precision medicine and explains how IVS is personalizing the drug development process with patient-derived and gene-edited human samples. The company's Novel Heart Tissue on a chip platform NuHeart™ enables rapid identification of the safety and efficacy profile of a given treatment for a specific patient group. IVS is saving time and money in developing new therapies while increasing the success rate of approval for cardio safe therapies.

#COVID19 #ChronicHeartFailure

InvivoSciences.com

Listen to the podcast here

Ayla Annac, CEO and Co-Founder, InvivoSciences shines light on the next generation of precision medicine and explains how IVS is personalizing the drug development process with patient-derived and gene-edited human samples. The company's Novel Heart Tissue on a chip platform NuHeart™ enables rapid identification of the safety and efficacy profile of a given treatment for a specific patient group. IVS is saving time and money in developing new therapies while increasing the success rate of approval for cardio safe therapies.

#COVID19 #ChronicHeartFailure

InvivoSciences.com

Download the transcript here